4DMedical’s XV Scanner deployed at the Prince of Wales Hospital in Sydney
General News

4DMedical’s XV Scanner deployed at the Prince of Wales Hospital in Sydney

4D Medical (ASX:4DX), up 30% after launching the world’s first dedicated lung scanner in Sydney

Australia has become the first place in the world to get a special 4D lung scanner that can give doctors an “unprecedented insight” into the organs.

In March 2022, 4DMedical announced that it had successfully developed and implemented the world’s first and only dedicated lung scanner, the XV Scanner, at the Prince of Wales Hospital in Sydney.

4DMedical's XV Scanner deployed at the Prince of Wales Hospital in Sydney

The scanner reached major milestones ahead of schedule under the Frontier Stage 2 initiative of the Australian federal government’s Medical Research Future Fund (MRFF). The development of the XV Scanner was funded by MRF F’s five-year grant of $28.9 million awarded to 4DMedical subsidiary Australian Lung Health Initiative Pty Ltd.

The XV Scanner integrates 4DMedical’s proprietary XV Technology™ software with purpose-built hardware, providing clinicians and patients with unprecedented and highly visual insight into respiratory function through automated scans.

4D Medical Managing Director and CEO Dr. Andreas Fouras said: “From the point of view of physicians and patients, the scanner represents a groundbreaking event in the global evolution of respiratory diagnoses.” Long Foundation CEO Mark Brooke said the device was a “breakthrough in innovation.”

“This new technology promises to revolutionize diagnostic and imaging procedures for a range of lung conditions that affect children, adults, and older Australians,” he said.

This unique and transformative XV TechnologyTM accurately and quickly scans lung function as the patient breathes, enabling early diagnosis and monitoring of changes over time.

Developed in Australia, the scanner also exposes patients to lower radiation levels than other devices. It can help patients who are extremely unwell and cannot be scanned by other devices.

The XV scanner paves the way for accelerated adoption into the company’s core SaaS product by facilitating access to XV Technology™ for more patients, including children and the critically ill (who cannot be scanned with conventional imaging equipment). At the same time, throughput is increased, and costs for healthcare providers are.

Respiratory diagnostics is a global industry worth $31 billion a year. 4DMedical is disrupting this sector and is committed to better informing doctors and patients about lung function.

Live XV 4D Scan – Static Image.

What exactly does the XV scanner do?

“In less than 10 seconds and for less radiation than one chest X-ray, you can get a full four-dimensional scan of a person’s lungs as they breathe,” explains Fouras.

“The scanner allows you to see in great detail where the air goes into the lungs and where the air doesn’t go — which is exactly what the doctors want to see,” Fouras said.

He added that the scanner is very safe because no radiation, dyes, or contrast agents are used in the scan.

It enables highly detailed maps of lung movement and function patterns, with functional deficits detected by local (regional) differences in activity.

“People can still use the X-ray scan invented more than a hundred years ago or this new special lung scanner that has multiple advantages over the X-ray,” Fouras said.

Australian Minister of Health and Aged Care MP Hon Greg Hunt said 4DMedical’s scanner would ultimately save lives and protect lives… as a company, I hope it could become the next Cochlear or Resmed, or CSL.

“Every Australian should be proud of this groundbreaking Australian-made medical technology platform,” Hunt said.

“The development of the XV Scanner is a wonderful example of Australia again rising above its weight in the world of health and medical research,” he said.

Australian Health Minister Greg Hunt discusses 4DMedical.

More than 73.4 million diagnostic lung procedures are performed annually in the United States alone, including in patients with; asthma, COPD, acute lower respiratory tract infections, pulmonary tuberculosis, lung cancer, and cystic fibrosis.


The TBN team is an established group of technology industry professionals with backgrounds in IT systems, business communications, and journalism.